With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.
Four investors returned to back the Duke University spinout, which is developing biased ligand small molecules.